WASHINGTON (dpa-AFX) - Monday, AbbVie Inc. (ABBV) announced that SKYRIZI has been listed for the treatment of moderately to severely active ulcerative colitis on the public drug formularies in Ontario and Alberta.
Additionally, Canada's Drug Agency has recommended SKYRIZI to be reimbursed with conditions by public drug plans.
'This is a testament to AbbVie's and the Health Institutions' continuous progress in expanding patient access to innovative medicines for inflammatory bowel disease' said Arima Ventin, Director, Market Access and Government Affairs, AbbVie Canada.
In the pre-market hours, ABBV is trading at $206.10, down 0.23 percent on the New York Stock Exchange.
Copyright(c) 2026 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2026 AFX News
